Sierra Oncology

June 05, 2019

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.

Does amount matter when it comes to a biotech IPO?

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Lilly scraps two research assets, leaving few rivals behind

Where is the IPO class of 2014-15 now?

Select small caps stand out amid wider 2016 stock market declines

Patience rewards Ionis and Ziarco

Returns hint at gradual decline in quality of biotech floats

Lively M&A scene keeps biotech shares buoyant in Q3

Genmab and Tesaro lead first-half gainers as Endo and Infinity falter

Bristol-Myers buys back Medarex discard

Asco event analyser – 2016’s winners and losers

Latest Reports

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

Evaluate Vantage 2021 Preview

Editor's Picks

2020 wins top of the froths for biotech stocks

Biotech flotations remain in high demand

Glaxo’s growth problem

Go or no go? Oncology decisions ahead for the FDA

Pfizer reveals its PD-1 secret